PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026ACS Bio & Med Chem Au0 citationsOpen Access

Discovery of Small-Molecule Antagonists of PHF1 and 19 Demonstrates the Ligandability of PRC2 Accessory Proteins

View Full Paper
IAIsabelle AmickRJRebecca L. JohnsonJLJiuyang Liu

Key Points

  • The aim is to discover small-molecule antagonists targeting the Tudor domains of PHF1 and PHF19 to inhibit their activity in gene repression.
  • Screened ∼1 K compounds from an internal library against PHF1 and PHF19 Tudor domains using TR-FRET assay.
  • Validated hit compound and conducted structure-activity relationship (SAR) studies to optimize binding.
  • Measured binding affinity using Kd values for the lead compound, UNC7242.
  • Identified UNC7242 as a lead compound with Kd of 1.13 ± 0.04 μM for PHF1 and 0.64 ± 0.14 μM for PHF19.
  • Demonstrated the ligandability of PHF1 and 19, implicating their potential as therapeutic targets.
  • SAR studies revealed insights into the binding mode of the antagonist.

Abstract

PHF1 and PHF19 are key accessory components of polycomb repressive complex 2 (PRC2) which is responsible for trimethylation at histone H3 lysine 27, ultimately leading to gene repression. PHF1 and 19 are known for their methyl-lysine reader Tudor domains that recognize methylated lysine 36 on H3, and they have also been implicated as drivers of a range of cancers, including multiple myeloma. Here, we describe the first small-molecule antagonist of the Tudor domains of PHF1 and 19. We screened an internal library of ∼ 1 K compounds against the Tudor domains using a TR-FRET assay. Upon validation of a hit compound, we performed structure–activity relationship (SAR) studies to better understand the binding mode and improve the affinity of the compound for the PHF1 and 19 Tudor domains. One such compound, UNC7242, which binds PHF1 with a Kd of 1.13 ± 0.04 μM and PHF19 with a Kd of 0.64 ± 0.14 μM, emerged as a lead compound. UNC7242 clearly demonstrates the ligandability of these disease-relevant proteins and serves as a starting point for the future development of potent and selective PHF1 and 19 chemical probes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Amick et al. (2026) studied this question.

synapsesocial.com/papers/69a91cf1d6127c7a504bfdc9https://doi.org/10.1021/acsbiomedchemau.5c00150
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A revised model for PHF20L1 Tudor function: DNA binding overrides methylation selectivity on nucleosomes2026
  2. 2Abstract 1933 Small molecule analysis of UHRF2 using fluorescence polarization2024
  3. 3Abstract 2423: Evaluation of novel small molecule inhibitors targeting Polycomb repressive complex 1 as chemical probes2026
  4. 4High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain2025
  5. 5PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma2025